NERV logo

NERV
Minerva Neurosciences Inc

9,557
Mkt Cap
$256.24M
Volume
63,027.00
52W High
$12.46
52W Low
$1.30
PE Ratio
-0.19
NERV Fundamentals
Price
$5.50
Prev Close
$5.55
Open
$5.54
50D MA
$6.43
Beta
0.80
Avg. Volume
199,033.72
EPS (Annual)
-$34.67
P/B
-0.95
Rev/Employee
$0.00
$16.58
Loading...
Loading...
News
all
press releases
Minerva Neurosciences (NASDAQ:NERV) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS
Minerva Neurosciences (NASDAQ:NERV - Get Free Report) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing...
MarketBeat·10d ago
News Placeholder
More News
News Placeholder
Minerva Neurosciences, Inc (NASDAQ:NERV) Short Interest Update
Minerva Neurosciences, Inc (NASDAQ:NERV - Get Free Report) was the target of a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling...
MarketBeat·14d ago
News Placeholder
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Citizens Jmp
Citizens Jmp began coverage on Minerva Neurosciences in a report on Wednesday. They set an "outperform" rating and a $14.00 target price for the company...
MarketBeat·30d ago
News Placeholder
Minerva Neurosciences, Inc (NASDAQ:NERV) Sees Significant Growth in Short Interest
Minerva Neurosciences, Inc (NASDAQ:NERV - Get Free Report) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,020,925...
MarketBeat·1mo ago
News Placeholder
Minerva Neurosciences (NASDAQ:NERV) Shares Cross Below Fifty Day Moving Average - Should You Sell?
Minerva Neurosciences (NASDAQ:NERV) Stock Passes Below Fifty Day Moving Average - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Short Interest in Minerva Neurosciences, Inc (NASDAQ:NERV) Grows By 27.8%
Minerva Neurosciences, Inc (NASDAQ:NERV - Get Free Report) saw a significant growth in short interest in March. As of March 13th, there was short interest totaling 559,530 shares, a growth of 27.8...
MarketBeat·2mo ago
News Placeholder
Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms
Minerva Neurosciences (NASDAQ:NERV) provided an update on its development program for roluperidone, which the company described as a potential first treatment option aimed at the negative symptoms of...
MarketBeat·2mo ago
News Placeholder
HC Wainwright Has Bullish Forecast for NERV Q1 Earnings
Minerva Neurosciences, Inc (NASDAQ:NERV - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for shares of Minerva Neurosciences in...
MarketBeat·2mo ago
News Placeholder
What is HC Wainwright's Forecast for NERV Q1 Earnings?
Minerva Neurosciences, Inc (NASDAQ:NERV - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Minerva Neurosciences in a research note issued to...
MarketBeat·2mo ago
News Placeholder
Minerva Neurosciences (NASDAQ:NERV) Issues Quarterly Earnings Results
Minerva Neurosciences (NASDAQ:NERV - Get Free Report) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping...
MarketBeat·2mo ago
<
1
2
...
>

Latest NERV News

View
Top Discussions